SCHEMBL5136301

SCHEMBL5136301

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(CC)Cc1ccc(C(C)C)cc1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CASR P41180 3/20 0.45
C5AR1 P21730 1/20 0.45
TSHR P16473 5/20 0.41
KDM4E B2RXH2 5/20 0.38
ALDH1A1 P00352 5/20 0.38
HPGD P15428 5/20 0.38
HSD17B10 Q99714 5/20 0.38
CYP3A4 P08684 4/20 0.38
HDAC1 Q13547 1/20 0.37
HSD11B1 P28845 2/20 0.36
NR1H3 Q13133 1/20 0.36
UCHL3 P15374 1/20 0.35
TP53 P04637 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
PDE4B Q07343 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL649659 0.95 CASR (0.46) CASRC5AR1TSHRKDM4EALDH1A1
SCHEMBL648044 0.93 CASR (0.44) CASRC5AR1TSHRKDM4EALDH1A1
SCHEMBL5138030 0.93 CASR (0.44) CASRC5AR1TSHRKDM4EALDH1A1
SCHEMBL5137883 0.90 TSHR (0.48) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5138038 0.90 C5AR1 (0.42) CASRC5AR1TSHRKDM4EALDH1A1
SCHEMBL5137312 0.89 C5AR1 (0.48) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5135643 0.89 C5AR1 (0.48) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5137931 0.89 GAA (0.47) CASRC5AR1TSHRKDM4EALDH1A1
SCHEMBL5135742 0.89 C5AR1 (0.40) CASRC5AR1TSHRKDM4EALDH1A1
SCHEMBL5136179 0.89 CASR (0.46) CASRC5AR1TSHRKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed